Please assess the completion status of the following clinical trial:

Trial Title: Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates admitted to the neonatal care unit (NCU) who suffer from late onset sepsis (LOS) at admission or during their NICU stay and receive meropenem for at least four days~Exclusion Criteria:~* Acute or chronic renal failure~* Hypersensitivity or allergy to meropenem

- Gender: ALL
- Minimum Age: 3 Days
- Maximum Age: 4 Weeks
- Healthy Volunteers: f

Study Arms:
- Infusion arm (Type: ACTIVE_COMPARATOR): Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
- Bolus group (Type: ACTIVE_COMPARATOR): Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).